Sanofi recently announced FDA approval for Sarclisa® (isatuximab-irfc) a monoclonal antibody (mAb) and CD-38 inhibitor for the treatment of relapsed, refractory multiple myeloma (RRMM).
The therapy is approved in combination with pomalidomide and dexamethasone (pom-dex). This combination offers an important new treatment option for patients in the United States living with this incurable disease.
Sarclisa® has Orphan Drug Designation status from both the FDA and the European Medicines Agency (EMA).
The name Sarclisa®, created by Origin is powerful, confident and re-assuring, derived from isatuximab and ‘targeted’, it is active sounding and conveys selectivity, care and strength, whilst being easy to pronounce and recall.
Origin have a strong representation of created brand names across the Oncology therapy area and more broadly the pharmaceutical spectrum and Sarclisa® provides another strong example of the type of name that can be achieved.